SCHEMBL23249797

SCHEMBL23249797

O=c1ccccc(-c2ncccc2F)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 3/20 0.46
HDAC2 Q92769 3/20 0.46
HDAC8 Q9BY41 3/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PTPRC P08575 2/20 0.44
CTSL P07711 1/20 0.44
CTSS P25774 1/20 0.44
PTPN13 Q12923 1/20 0.44
TDP2 O95551 1/20 0.44
NSD2 O96028 1/20 0.44
ABL1 P00519 1/20 0.44
PLCG1 P19174 1/20 0.44
CES1 P23141 1/20 0.44
PAX8 Q06710 1/20 0.44
RIN1 Q13671 1/20 0.44
MEN1 O00255 1/20 0.44
THRB P10828 1/20 0.44
BLM P54132 1/20 0.44
KMT2A Q03164 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29890029 1.00 HDAC4 (0.46) HDAC4HDAC2HDAC8HDAC6PTPRC
SCHEMBL28480001 0.79 KDM4E (0.50) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL23249863 0.73 HDAC4 (0.59) HDAC4HDAC2HDAC8HDAC6MEN1
SCHEMBL6174571 0.72 MAPT (0.55) TDP1KDM4ELMNAALDH1A1
SCHEMBL1176958 0.72 GABRG2 (0.44) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL15317422 0.72 KDM4E (0.54) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL15624391 0.71 TDP1 (0.44) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL23263205 0.70 TRPV1 (0.36) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL19201009 0.70 TDP1 (0.42) PTPRCCTSLCTSSPTPN13TDP2
SCHEMBL17045827 0.69 S100A4 (0.44) PTPRCCTSLCTSSPTPN13TDP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073131-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) 2024-04-04 WO disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
EP-4045025-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 EP disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 WO disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB HDAC4 2098/4885HDAC2 2698/4885HDAC8 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.